ut its association with response to taxane-based chemotherapy is not clear. Dennis J. Slamon, M.D., Ph.D., of the University of California, Los Angeles, and colleagues analyzed retrospective data from a randomized clinical trial that had treated patients with metastatic breast cancer with either taxane-based epirubicinpaclitaxel (ET) chemotherapy or epirubicincyclophosphamide (EC) chemotherapy.
They found that HER-2/neu overexpression does not adversely influence response to first-line ET or EC chemotherapy and that a taxane-containing regimen, such as ET, may provide a preferential benefit to patients with tumors that overexpress HER-2/neu.
Contact: Kim Irwin, Women's Cancer Program Area, Jonsson Cancer Center, 310-206-2805, email@example.com
Researchers Examine Targeted Therapy for Neuroblastoma in Mouse Model
Survival is poor in patients with advanced-stage neuroblastoma, a cancer of nerve cells in infants and children, and there is a need to develop better treatments. Mirco Ponzoni, Ph.D., of G. Gaslini Children's Hospital in Genoa, Italy, and colleagues show that by encapsulating an antisense oligonucleotide targeting an oncogene and activating the innate immune system in a liposome that specifically targets neuroblastoma cells, neuroblastoma-bearing mice lived longer than mice given any other treatment in the study.
Contact: Mirco Ponzoni, G. Gaslini Children's Hospital, 39-010-563-6342, firstname.lastname@example.org
Also in the August 4 JNCI:
No Survival Benefit for Adjuvant Chemotherapy for Colon Cancer after 10 Years:
Activated Signaling Pathway May Predict Lung Cancer Patients' Response to Gefitinib:
Contact: Sarah L. Zielinski
Journal of the National Cancer Institute 3-Aug-2004Page: 1 2 3 Related biology news :1
. Other highlights in the September 1 JNCI2
. Other highlights in the August 18 JNCI3
. Other highlights in the July 7 JNCI4
. Other highlights in the June 16 JNCI5
. Other Highlights in the June 2 JNCI6
. Other highlights in the May 19 JNCI7
. Other highlights in the May 5 JNCI8
. Other highlights of the March 17 issue of JNCI9
. Other highlights in the March 3 issue of JNCI10
. Other highlights in the February 18 issue of JNCI11
. Other highlights in the February 4 issue of JNCI